Investment Thesis
Surrozen exhibits severe balance sheet deterioration with negative stockholders' equity of -$187.8M, indicating technical insolvency. The company burns ~$30M annually with only $3.5M in revenue and no growth trajectory, creating an unsustainable cash situation despite adequate near-term liquidity. Fundamental viability depends entirely on external capital raises or transformative clinical outcomes, both representing high-risk catalysts.
Strengths
- Cash position of $89.2M provides 2-3 years of runway at current burn rate
- Strong liquidity ratios (9.22x current/quick) ensure near-term operational continuity
- Active insider participation (11 Form 4 filings) suggests management engagement with company direction
Risks
- Negative stockholders' equity of -$187.8M indicates technical insolvency and balance sheet impairment
- Operating cash burn of -$30.2M annually is unsustainable without external financing or revenue acceleration
- Minimal revenue of $3.5M with 0% YoY growth provides no evidence of commercial viability or path to profitability
- Liabilities of $286.5M exceed assets by $187.8M, creating significant capital structure risk and dilution potential
- Negative margins across all profitability metrics (-6960.8% net margin, -1210.6% operating margin)
Key Metrics to Watch
- Stockholders' equity trend - movement toward positive equity is critical for solvency
- Cash burn rate and cash runway - any material change impacts survival timeline
- Revenue growth acceleration - evidence of commercial traction or partnership deals
- Operating cash flow trajectory - path to sustainable cash generation
Financial Metrics
Revenue
3.5M
Net Income
-242.0M
EPS (Diluted)
$-32.37
Free Cash Flow
-30.4M
Total Assets
98.7M
Cash
89.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,210.6%
Net Margin
-6,960.8%
ROE
N/A
ROA
-245.1%
FCF Margin
-873.5%
Balance Sheet & Liquidity
Current Ratio
9.22x
Quick Ratio
9.22x
Debt/Equity
N/A
Debt/Assets
290.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-16T14:42:22.076920 |
Data as of: 2025-12-31 |
Powered by Claude AI